Cns Pharmaceuticals Inc (CNSP)

Jul 25, 2025

CNS Pharmaceuticals Inc. Stock Analysis and ForecastFree Market Dynamics Reports - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

What drives CNS Pharmaceuticals Inc. stock priceFree Stock Movement Tracking - Autocar Professional

Jul 25, 2025

Jul 23, 2025

What analysts say about CNS Pharmaceuticals Inc. stockFree Consultation - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Is CNS Pharmaceuticals Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Why CNS Pharmaceuticals Inc. stock attracts strong analyst attentionPrecision Entry Strategy - beatles.ru

Jul 22, 2025

Jul 22, 2025

CNS Pharmaceuticals Announces Reverse Stock Split - TipRanks

Jul 22, 2025

Jul 22, 2025

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference - 富途牛牛

Jul 22, 2025

Jul 22, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) CEO Featured In Virtual Investor Summer Spotlight Conference - Barchart.com

Jul 22, 2025

Jul 22, 2025

CNS Pharmaceuticals CEO Shares Brain Cancer Treatment Vision at Investor Conference | CNSP Stock News - Stock Titan

Jul 22, 2025

Jul 20, 2025

CNS Pharmaceuticals To Carry Out 1-for-12 Reverse Stock Split On July 22nd, 2025 - 富途牛牛

Jul 20, 2025

Jul 20, 2025

CNS Pharmaceuticals Implements 1-for-12 Reverse Stock Split to Consolidate Shares and Improve Market Position - AInvest

Jul 20, 2025

Jul 19, 2025

Published on: 2025-07-19 01:04:34 - jammulinksnews.com

Jul 19, 2025

Jul 18, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22 - Barchart.com

Jul 18, 2025

Jul 18, 2025

CNS Pharmaceuticals announces 1-for-12 reverse stock split By Investing.com - Investing.com Nigeria

Jul 18, 2025

Jul 18, 2025

CNS Pharmaceuticals announces 1-for-12 reverse stock split - Investing.com

Jul 18, 2025

Jul 18, 2025

Brain Cancer Drug Developer CNS Pharmaceuticals Announces 1:12 Reverse Split to Maintain Nasdaq Listing - Stock Titan

Jul 18, 2025

Jul 15, 2025

How CNS Pharmaceuticals Inc. stock performs during market volatility3x Growth Potential - Newser

Jul 15, 2025

Jul 15, 2025

CNS Pharmaceuticals Posts Investor Presentation on Brain Cancer - TipRanks

Jul 15, 2025

Jul 15, 2025

CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 15, 2025

Jul 15, 2025

What makes CNS Pharmaceuticals Inc. stock price move sharplySmart Money Trade Setups - Newser

Jul 15, 2025

Jul 15, 2025

Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform - Yahoo Finance

Jul 15, 2025

Jul 10, 2025

Jazz Looks To Block Avadel From Asking For Sleep Drug OK - Law360

Jul 10, 2025

Jul 10, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Lead Program In Virtual CEO Segment - Barchart.com

Jul 10, 2025

Jul 09, 2025

CNS Pharmaceuticals: TPI 287 Shows Potential in Treating CNS Tumors, CEO Discusses Recent Clinical Data at Virtual Investor CEO Connect Segment - AInvest

Jul 09, 2025

Jul 09, 2025

CNS Pharma CEO Shares Exclusive Insights on Novel Brain Cancer Treatment TPI 287 at Healthcare Leaders Meeting - Stock Titan

Jul 09, 2025

Jul 09, 2025

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment - FinancialContent

Jul 09, 2025

Jul 04, 2025

CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 2% – Here’s What Happened - Defense World

Jul 04, 2025

Jun 25, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Highlights GBM Treatment Insights In KOL Segment Featuring Dr. Erin Dunbar - Barchart.com

Jun 25, 2025

Jun 24, 2025

CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment with Dr. Erin Dunbar - citybuzz -

Jun 24, 2025